Company profile for Orphan Technologies

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Orphan Technologies is dedicated to developing novel therapies to dramatically improve the lives of patients suffering from the rare disorder, classical homocystinuria, and related diseases. OT-58, our lead drug development candidate, has been optimized as an enzyme therapy for classical homocystinuria, a genetic disease characterized by debilitating cardiovascular, skeletal, neurologic, and ophthalmologic complications. OT-58...
Orphan Technologies is dedicated to developing novel therapies to dramatically improve the lives of patients suffering from the rare disorder, classical homocystinuria, and related diseases. OT-58, our lead drug development candidate, has been optimized as an enzyme therapy for classical homocystinuria, a genetic disease characterized by debilitating cardiovascular, skeletal, neurologic, and ophthalmologic complications. OT-58 is designed to reduce homocysteine levels via a targeted mechanism of action and may have therapeutic applications in other diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Switzerland
Address
Address
Zuercherstrasse 19 CH-8640 Rapperswil
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.biospace.com/article/releases/retrophin-completes-acquisition-of-orphan-technologiesaddition-of-ot-58-strengthens-pipeline-of-potential-first-in-class-therapies-targeting-rare-diseases/?s=79

BIOSPACE
12 Nov 2020

http://ir.retrophin.com/news-releases/news-release-details/retrophin-announces-agreement-acquire-orphan-technologies#:~:text=(NASDAQ%3A%20RTRX)%20today%20announced,of%20classical%20homocystinuria%20(HCU).

PRESS RELEASE
23 Oct 2020

https://www.biospace.com/article/releases/retrophin-announces-agreement-to-acquire-orphan-technologies/?s=79

BIOSPACE
22 Oct 2020

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty